GRAIL Reports NHS Galleri Trial Results Showing Fewer Stage IV Cancer Diagnoses

June 01, 2026
GRAIL presented full results from the NHS-Galleri trial at the 2026 ASCO Annual Meeting, showing a reduction in Stage IV cancer diagnoses and increased detection rates when the Galleri test was added to standard screening.

GRAIL announced in a press release full results from its NHS-Galleri trial presented at the 2026 ASCO Annual Meeting. The study evaluated annual screening with the Galleri test across England’s National Health Service over three years, involving 142,250 participants aged 50 to 77.

The trial showed that using the Galleri test reduced Stage IV diagnoses of 12 prespecified cancers by 22 percent in the second screening round and 26 percent in the third. When added to standard care screening, the test led to a fourfold increase in the cancer detection rate and a 25 percent reduction in diagnoses made through emergency presentation.

No statistically significant reduction was observed in the combined primary endpoint of Stage III and IV cancers. The NHS-Galleri trial aims to assess whether early detection through blood-based screening can identify cancers at more treatable stages.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly, AI Policy Brief or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Safety & Regulation AI Brief AI Brief (X)

More from: Life Sciences

06/01
3billion Launches Genomic Newborn Screening Service 3B-NEO
05/29
Nucs AI and AstraZeneca Collaborate on AI Response Prediction for Radioconjugate Research
05/29
Holmusk Expands NeuroBlu Dataset to 46 Million Patients with Neurology and Biomarker Data
05/29
SKIA HEAD AR Surgical Guidance System Gains FDA Clearance
05/29
Cognizant Opens TriZetto Unify Platform to AI Agents for Prior Authorization

More from: AI Safety

06/01
DMind AI Study Finds No AI Model Ready for Web3 Safety Tasks
05/30
NIST Expands AI Consortium and Invites New Members
05/27
Einride Partners with TUV SUD for Independent Verification of Autonomous Safety Governance
05/26
Crew Scaler Publishes Comprehensive Study on Multi-Agent AI Security
05/26
TELUS Digital Publishes Benchmark on Generative AI Safety Risks

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like